In April 2019, Novosanis signed a worldwide, non-exclusive distribution agreement with Fujirebio, a global leader in the field of in vitro diagnostics (IVD), for use of Colli-Pee® with Fujirebio’s INNO-LiPA HPV genotyping Extra II assay. The INNO-LiPA HPV genotyping Extra II assay has also been CE marked for use with UCM preserved first-void urine (FVU) collected via Colli-Pee® .
The agreement enables detection of Human Papillomavirus (HPV) in FVU samples. HPV is a common sexually transmitted infection (STI), which has been linked to cause several types of cancers such as cervical cancer.
“FVU has been shown to contain higher amounts of HPV DNA compared to a random or midstream urine sample. Therefore, the use of a volumetric and standardized urine collection method such as Colli-Pee®, which can capture FVU effectively allows more accurate detection with the INNO-LiPA assay,” says Vanessa Vankerckhoven, CEO of Novosanis. “Urine offers several benefits by allowing for private, easy and painless collection,‘’ she continued.